GlassScriptPhysician profile
Raymond Y Chan
NPI 1730298373
$40,959.35
in general payments reported to CMS, 2019-2025
8 companies · $2,843 in 2025
The $2,843 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $2,026 · 2021: $7,653 · 2022: $7,905 · 2023: $4,288 · 2024: $2,905 · 2025: $2,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,464 · Food and Beverage: $1,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,463.75 |
| Food and Beverage | $1,571.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $15,258.96 | 2019-2024 | Cequa |
| Allergan, INC. | $9,718.96 | 2019-2022 | |
| Abbvie INC. | $8,503.24 | 2023-2025 | Botox |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $6,002.16 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $1,072.22 | 2022-2025 | Vyzulta, Miebo |
| Shire North American Group INC | $270.85 | 2019 | |
| Aerie Pharmaceuticals, INC. | $106.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.40 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.